Literature DB >> 26530735

RIG-I-like receptors and autoimmune diseases.

Hiroki Kato1, Takashi Fujita2.   

Abstract

Type I interferon (IFN) plays an essential role in antiviral innate immune responses and also in adaptive immune responses. Defects in the production of IFN markedly increase susceptibility to viral invasion and attenuate the acquired immunity. Recently an increased expression of type I IFN, also termed IFN signature, has been reported in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and Aicardi-Goutières syndrome (AGS). The evidence clearly shows that the initiation and termination of IFN production should be tightly controlled. RIG-I-like receptors (RLRs) are viral RNA sensors and are essential for type I IFN induction. We herein summarize recent reports on RLR mutations in patients and MDA5 mutant mice, and discuss possible mechanisms by which aberrant activation of RLRs can cause autoimmunity.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26530735     DOI: 10.1016/j.coi.2015.10.002

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  25 in total

Review 1.  Negative regulators of the RIG-I-like receptor signaling pathway.

Authors:  Kendra M Quicke; Michael S Diamond; Mehul S Suthar
Journal:  Eur J Immunol       Date:  2017-04       Impact factor: 5.532

2.  B Cells Produce Type 1 IFNs in Response to the TLR9 Agonist CpG-A Conjugated to Cationic Lipids.

Authors:  Munir Akkaya; Billur Akkaya; Pietro Miozzo; Mukul Rawat; Mirna Pena; Patrick W Sheehan; Ann S Kim; Olena Kamenyeva; Juraj Kabat; Silvia Bolland; Akanksha Chaturvedi; Susan K Pierce
Journal:  J Immunol       Date:  2017-06-26       Impact factor: 5.422

Review 3.  Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

Authors:  Aikaterini Thanou; Eldon Jupe; Mohan Purushothaman; Timothy B Niewold; Melissa E Munroe
Journal:  J Autoimmun       Date:  2021-02-22       Impact factor: 7.094

4.  DUSP1 regulates apoptosis and cell migration, but not the JIP1-protected cytokine response, during Respiratory Syncytial Virus and Sendai Virus infection.

Authors:  Alexa C Robitaille; Elise Caron; Nicolas Zucchini; Espérance Mukawera; Damien Adam; Mélissa K Mariani; Anaïs Gélinas; Audray Fortin; Emmanuelle Brochiero; Nathalie Grandvaux
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

Review 5.  Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.

Authors:  Misako Matsumoto; Yohei Takeda; Megumi Tatematsu; Tsukasa Seya
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

6.  Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.

Authors:  Yat Yee Wong; Brian Johnson; Thomas C Friedrich; Lauren A Trepanier
Journal:  Pharmacol Res Perspect       Date:  2017-04-26

Review 7.  Viral evasion of intracellular DNA and RNA sensing.

Authors:  Ying Kai Chan; Michaela U Gack
Journal:  Nat Rev Microbiol       Date:  2016-05-13       Impact factor: 60.633

8.  RNAs Containing Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate Immune Signaling.

Authors:  Ann Fiegen Durbin; Chen Wang; Joseph Marcotrigiano; Lee Gehrke
Journal:  mBio       Date:  2016-09-20       Impact factor: 7.867

9.  Bioinformatics identification of key candidate genes and pathways associated with systemic lupus erythematosus.

Authors:  Fangyuan Yang; Zeqing Zhai; Xiaoqing Luo; Guihu Luo; Lili Zhuang; Yanan Zhang; Yehao Li; Erwei Sun; Yi He
Journal:  Clin Rheumatol       Date:  2019-11-01       Impact factor: 2.980

10.  Caspase-Dependent Cleavage of DDX21 Suppresses Host Innate Immunity.

Authors:  Wei Wu; Yang Qu; Shengqing Yu; Sa Wang; Yuncong Yin; Qinfang Liu; Chunchun Meng; Ying Liao; Zaib Ur Rehman; Lei Tan; Cuiping Song; Xusheng Qiu; Weiwei Liu; Chan Ding; Yingjie Sun
Journal:  mBio       Date:  2021-06-14       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.